Skip to main content

Table 1 Clinical characteristics of patients in the NGS and in the PCR cohort. In the NGS cohort 10 patients had Gleason score 7a (3 + 4) and 10 patients had Gleason score 7b (4 + 3), and 13 and 7 patients were classified as intermediate and aggressive risk, respectively, using the D’Amico Risk Classification

From: Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes

   Discovery cohort (RNA-seq) Validation cohort (RT-qPCR)
  Control Patient Control Patient
Number   9 20 19 28
Age (median, years)   58 66 56 67
Gleason Scorea   nd   nd  
  7   20   21
  8–10     7
Clinical T-stagingb   nd   nd  
  T1   11   12
  T2   6   9
  T3   3   7
PSAb (ng/mL)   nd 8.8 nd 13.5
  1. Nd non determined
  2. aGleason Score in biopsy tissue. bClinical T-staging and PSA levels (ng/mL) at time of diagnosis